Penn’s one-stop solution for technology commercialization and entrepreneurship
I’m a Faculty Member or Researcher
I’m with a Company
I’m an Entrepreneur
I want to:
Translating Discoveries
PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.
We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
I-Corps Cohort Applications Now Open
Special Bio/Medtech I-Corps September 2025
- Starts Sep-12.
- Apply by Sep-2.
- Fully virtual program run by the MidAtlantic I-Corps HUB.
- More information here.
Regular I-Corps cohort – October 2025
- Apply by Sep-21 (priority) or Sep-28 (general). Apply here.
Penn Startups Raising Capital in 2025
Learn about which Penn startup companies are raising capital in 2025 with this comprehensive list. With companies in connected health, digital health, diagnostics, therapeutics, and medical devices, Penn offers a wide range of rapidly emerging companies at all investment levels.
If you are interested in connecting about these startups, please email Laurie Actman (lactman@upenn.edu).
Download and view the complete list
Available Technologies
Find technology opportunities by sector or search:
Nanotechnology | Antibody | Optics & Photonics | Medical Devices | COVID-19 | Immunology | Oncology | Materials | Bioengineering | Neurodegenerative Diseases
View all technologies
Recent News
All NewsRead the PCI FY24 Year in Review
1500
Active Commercial Partnership Agreements
150+
Active Penn Spinouts (152)
125
Issued U.S. Patents (+20% from FY23)
#13
Nationally for Utility Patents (NAI Worldwide Universities Granted US Utility Patents)
Discover CAR T-cell technology at Penn
Our latest CAR T-cell enhancement portfolio features innovations poised to transform treatment efficacy with boosted cytokine activity/metabolism, streamlined manufacturing, and reduced T-cell exhaustion. Join us in turning lab discoveries into real-world impact through licensing opportunities with PCI.